dr. camidge on mechanisms of resistance to tkis in nsclc
Published 5 years ago • 185 plays • Length 1:58Download video MP4
Download video MP3
Similar videos
-
1:52
dr. camidge on optimal therapy in egfr nsclc
-
5:46
resistance mechanisms in egfr nsclc
-
4:32
resistance mechanisms in egfr-positive nsclc
-
3:48
mechanisms of resistance to upfront egfr-targeted therapy
-
0:58
dr. camidge on inhibiting initial activating egfr mutations and the t790m resistance mutation
-
7:51
nsclc: egfr inhibition and resistance mechanisms
-
0:55
dr. reimuth discusses studies looking at resistance to egfr tkis in nsclc
-
1:41
dr. goldberg on resistance to osimertinib for nsclc
-
1:00
dr. camidge on phase i study with azd9291 in nsclc
-
1:51
dr. camidge discusses treatment of patients with alk nsclc
-
6:14
third-generation egfr inhibitors in nsclc
-
1:34
dr. camidge on the alta study of brigatinib in nsclc
-
4:18
dr. ross camidge on the ever changing world of clinical cancer research
-
8:31
resistance mechanisms and sequencing for egfr nsclc
-
1:51
dr. camidge on biomarker combinations in nsclc
-
1:55
dr. d. ross camidge on targeted therapies in adjuvant non-small cell lung cancer
-
1:09
dr. camidge on crizotinib as a ros1 inhibitor in nsclc
-
1:53
resistance to osimertinib in egfr-mutated nsclc
-
5:52
treatment of egfr nsclc after osimertinib